argenx's acquisition of Unnatural Products adds macrocyclic peptides that could yield oral or long-acting treatments for immune-mediated diseases.
|Articles|August 26, 2020
DWK Life Sciences to Acquire Müller + Müller
Author(s)BioPharm International Editors
Müller + Müller will become part of DWK upon closing in September 2020 and will continue to function under the same name and management.
Advertisement
DWK Life Sciences announced on August 26, 2020 that it has acquired Müller + Müller, a German manufacturer of primary packaging materials made of tubular glass for the pharmaceutical industry.
Under the terms of the acquisition, Müller + Müller will become part of DWK upon closing in September 2020, a DWK press release said. Müller + Müller will continue to function under the same name and will be managed by its current CEO, Florian Müller-Stauch.
“Acquiring the family business Müller + Müller is a significant strategic step for us in expanding our activities in the market for pharmaceuticals packaging,” explained CEO of DWK Life Sciences, Armin Reiche, in the press release. “We are not just investing in an important growth market here, but also in a company that boasts first class production technology and highly reliable products.”
“Driven by the high demand of the vaccine industry for vials, expansion of our production capacities is the next logical step,” added Müller-Stauch, in the press release. “We are delighted to have found a strong and reliable partner in DWK who will allow us to further develop our business.”
Source:
Advertisement
Related to this article
ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.
Beam’s base-edited cell therapy met its primary endpoint in the BEACON trial, and a U.S. biologics license application is planned as early as year-end.
AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.
Merck's GLP-1/glucagon co-agonist raised MASH resolution versus placebo at 52 weeks, but fibrosis and dose-response questions remain.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5